Document is current
Any future updates will be listed below
-
Authors
Toenders, Yara J. https://orcid.org/0000-0002-4117-1143
Laskaris, Liliana
Davey, Christopher G. https://orcid.org/0000-0003-1431-3852
Berk, Michael
Milaneschi, Yuri https://orcid.org/0000-0002-3697-6617
Lamers, Femke https://orcid.org/0000-0003-4344-5766
Penninx, Brenda W. J. H.
Schmaal, Lianne https://orcid.org/0000-0001-9822-048X
-
Funding
Funding for this research was provided by:
Department of Health | National Health and Medical Research Council (1140764, 141738, 1156072)
Wellcome Trust Mental Health Priority Area 'Active Ingredients'
Wellcome Trust Mental Health Priority Area 'Active Ingredients'
ZonMw (636310017)
- License Information
-
More Information
Article History
Received: 30 July 2021
Revised: 12 August 2021
Accepted: 13 September 2021
First Online: 11 October 2021
Competing interests
: MB is a co-inventor of two provisional patents regarding the use of NAC and related compounds for psychiatric indications, which, while assigned to the Mental Health Research Institute, could lead to personal remuneration upon a commercialisation event. MB has served as a speaker for Astra Zeneca, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Janssen Cilag, Lundbeck, Merck, Pfizer, Sanofi Synthelabo, Servier, Solvay, and Wyeth; and has served as a consultant to Astra Zeneca, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Janssen Cilag, Lundbeck Merck, and Servier. BP has received (non-related) research funding from Jansen Research and Boehringer Ingelheim. The other authors report no competing interests.
